Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 915-928 , October 2006

B cell depletion therapy in rheumatic disease

  • J.C.W. Edwards, MD (Professor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 20 7380 9215; Fax: +44 20 7380 9278.

References 

  1. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Seminars in Oncology. 2002;29(supplement 2):105–112
  2. Edwards JC, Cambridge G. Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen. British Journal of Rheumatology. 1998;37:126–130
  3. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology. 1999;52:1701–1704
  4. Zaja F, Russo D, Fuga G, et al. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology. 2000;55:1062–1063
  5. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952–957
  6. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British Journal of Haematology. 2004;125:232–239
  7. Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease?. Immunology. 1999;97:1868–1896
  8. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology. 2001;40:205–211
  9. Edwards JC, Cambridge G. Is rheumatoid arthritis a failure of B cell death in synovium?. Annals of the Rheumatic Diseases. 1995;54:696–700
  10. Fearon DT, Carter RH. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annual Review of Immunology. 1995;13:127–149
  11. Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. Journal of Experimental Medicine. 1991;173:487–489
  12. Mannik M, Nardella FA. IgG rheumatoid factors and self-association of these antibodies. Clinics in Rheumatic Diseases. 1985;11:551–572
  13. Dieterich W, Ehnis T, Bauer M, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nature Medicine. 1997;3:797–801
  14. Kaliyaperumal A, Michaels MA, Datta SK. Naturally processed chromatin peptides reveal a major autoepitope that primes pathogenic T and B cells of lupus. Journal of Immunology (Baltimore, Md.: 1950). 2002;168:2530–2537
  15. Nardella FA, Dayer JM, Roelke M, et al. Self-associating IgG rheumatoid factors stimulate monocytes to release prostaglandins and mononuclear cell factor that stimulates collagenase and prostaglandin production by synovial cells. Rheumatology International. 1983;3:183–186
  16. Bhatia A, Blades S, Cambridge G, Edwards JC. Differential distribution of FcγRIIIa in normal human tissues and co-localization with DAF and fibrillin-1: implications for immunological microenvironments. Immunology. 1998;94(1):56–63
  17. Abrahams VM, Cambridge G, Edwards JC. Induction of tumour necrosis factor alpha production by human monocytes: a key role for FcγRIIIa in rheumatoid arthritis. Arthritis and Rheumatism. 2002;43:608–616
  18. Maini RN, Elliott M, Brennan FM, et al. TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis. APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 1997;105:257–263
  19. Davies KA, Hird V, Stewart S, et al. A sudy of in vivo immune complex formation and clearance in man. Journal of Immunology (Baltimore, Md.: 1950). 1990;144:4613–4620
  20. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis and Rheumatism. 2003;48:455–459
  21. Teeling JL, French RR, Cragg MS, et al. Characterisation of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphomas. Blood. 2004;104:1793–1800
  22. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. Journal of Immunology (Baltimore, Md.: 1950). 2005;174:817–826
  23. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimaeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–445
  24. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Annals of the Rheumatic Diseases. 2002;61:883–888
  25. Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders. Biochemical Society Transactions. 2002;30:824–828
  26. Edwards JC, Leandro MJ, Cambridge G. B Lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheumatic Diseases Clinics of North America. 2004;30:393–404
  27. Cambridge G, Leandro MJ, Edwards JC, et al. Serological changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis and Rheumatism. 2003;48:2146–2154
  28. Leandro MJ, Ehrenstein MR, Cambridge G, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis and Rheumatism. 2006;54:613–620
  29. Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator (BLyS) in rituximab-treated rheumatoid arthritis patients: relation to B cell depletion, circulating antibodies, and clinical relapse. Arthritis and Rheumatism. 2006;54:723–732
  30. De Vita S, Zaja F, Sacco S, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis and Rheumatism. 2002;46:2029–2033
  31. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B cell targeted therapy with rituximab in rheumatoid arthritis. The New England Journal of Medicine. 2004;35:2572–2581
  32. Moore J, Ma D, Will R, et al. A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplantation. 2004;34:241–247
  33. Kneitz C, Wilhelm M, Tony HP. Improvement of refractory rheumatoid arthritis after depletion of B cells. Scandinavian Journal of Rheumatology. 2004;33:82–86
  34. Swords R, Power D, Fay M, et al. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). American Journal of Hematology. 2004;77:103–104
  35. Emery P, Fleischmann RM, Filipowicz-Sosnowska A, et al. Rituximab in rheumatoid arthritis: a double blind placebo controlled dose-ranging study. Arthritis and Rheumatism. 2005;52(supplement):S709
  36. Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis and Rheumatism. 2002;46:2673–2677
  37. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis and Rheumatism. 2004;50:2580–2589
  38. van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E, et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scandinavian Journal of Rheumatology. 2004;33:423–427
  39. Leandro MJ, Cambridge G, Edwards JC. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005;44:1542–1545
  40. Ng K, Leandro MJ, Edwards JC et al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Annals of the Rheumatic Diseases [in press].
  41. Tahir H, Rohrer J, Bhatia A, et al. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford). 2005;44:561–562
  42. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis and Rheumatism. 2005;52:3168–3174
  43. Specks U, Fervenza FC, McDonald TJ, Hogan MCE. Response of Wegener's granulomatosis to anti-CD20 chimaeric monoclonal antibody therapy. Arthritis and Rheumatism. 2001;44:2836–2840
  44. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and Rheumatism. 2005;52:262–268
  45. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. Journal of Internal Medicine. 2005;257:540–548
  46. Bhatia A, Ell PJ, Edwards JC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Annals of the Rheumatic Diseases. 2005;64(7):1099–1100
  47. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis and Rheumatism. 2005;52:601–607
  48. Lambotte O, Kolb R, Maigne G, et al. Efficacy of rituximab in refractory polymyositis. The Journal of Rheumatology. 2005;32:1369–1370
  49. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis and Rheumatism. 2005;52:2740–2750
  50. Erdozain JG, Ruiz-Irastorza G, Egurbide MV, Aguirre C. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica. 2004;89:ECR34
  51. Protheroe A, Edwards JC, Simmons A, et al. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Rheumatology (Oxford). 1999;38:1150–1152
  52. Singh F, Weinberg JM. Partial remission of psoriasis following rituximab therapy for non-Hodgkin lymphoma. Cutis; Cutaneous Medicine for the Practitioner. 2005;205:186–188
  53. Papadakis KA, Rosenbloom B, Targan SR. Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease. Gastroenterology. 2003;124:583
  54. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Annals of the Rheumatic Diseases. 2005;64:913–920
  55. Shan D, Press OW, Tsu TT, et al. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. Journal of Immunology (Baltimore, Md.: 1950). 1999;162:6589–6595
  56. Kaufman J, Wegener WA, Horpick JD, et al. Initial clinical study of immunotherapy in SLE using epratuzumab (humanized anti-CD22 antibody). Arthritis and Rheumatism. 2004;50:S447
  57. Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity. 2001;15:289–302
  58. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis and Rheumatism. 2003;48:3253–3265
  59. Wong BR, Grossbard EB, Payan DG, Masuda ES. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opinion on Investigational Drugs. 2004;13:743–762

PII: S1521-6942(06)00070-2

doi: 10.1016/j.berh.2006.05.010

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 915-928 , October 2006

Article Tools